Last updated: September 4, 2026
The halobetasol propionate and tazarotene combination is marketed in the United States as Duobrii lotion, a once-daily topical treatment for plaque psoriasis in adults. The product combines a high-potency corticosteroid with a topical retinoid and occupies a differentiated position among nonbiologic psoriasis therapies. Its commercial value depends on brand access, payer coverage, physician adoption, and the timing of generic entry.
Duobrii has meaningful clinical differentiation but limited public financial transparency. Bausch Health and Ortho Dermatologics do not report product-level revenue, so the product’s exact sales trajectory cannot be independently quantified from public filings. The commercial outlook is positive in branded topical dermatology but exposed to reimbursement restrictions, competing nonsteroidal products, and potential 505(b)(2) or generic competition.
What is halobetasol propionate and tazarotene used for?
Duobrii contains halobetasol propionate 0.01% and tazarotene 0.045% in a topical lotion. The FDA approved it in May 2019 for the topical treatment of plaque psoriasis in adults. Treatment is applied once daily for up to eight weeks. The product is not intended for oral, ophthalmic, intravaginal, or intrarectal use. It is also not labeled for use on the face, groin, or axillae because of the risk profile associated with a super-high-potency corticosteroid. [1]
| Attribute |
Duobrii |
| Active ingredients |
Halobetasol propionate 0.01%; tazarotene 0.045% |
| Dosage form |
Topical lotion |
| FDA approval |
May 2019 |
| Indication |
Plaque psoriasis in adults |
| Dosing |
Once daily |
| Maximum labeled treatment period |
Eight weeks |
| Commercial sponsor |
Ortho Dermatologics, a Bausch Health business |
| Regulatory category |
New drug application, topical fixed-dose combination |
| Main therapeutic role |
Nonbiologic topical treatment for plaque psoriasis |
The combination is designed to balance two mechanisms. Halobetasol rapidly suppresses inflammation and hyperproliferation. Tazarotene normalizes keratinocyte differentiation and may support longer-term disease control. The formulation gives prescribers one product rather than separate corticosteroid and retinoid prescriptions.
How large is the market for topical plaque psoriasis drugs?
The addressable market is broad, but Duobrii competes in a crowded segment. Topical corticosteroids remain the most commonly used prescription treatments for mild-to-moderate psoriasis. Combination products compete with low-cost generic steroids, vitamin D analogues, retinoids, phosphodiesterase-4 inhibitors, aryl hydrocarbon receptor agonists, and topical Janus kinase or other emerging mechanisms.
Key competitors include:
| Product |
Active ingredient or class |
Competitive position |
| Duobrii |
Halobetasol propionate plus tazarotene |
High-potency steroid plus retinoid in one lotion |
| Wynzora |
Calcipotriene plus betamethasone dipropionate |
Non-greasy cream formulation with combination activity |
| Enstilar |
Calcipotriene plus betamethasone dipropionate |
Foam delivery system |
| Taclonex |
Calcipotriene plus betamethasone dipropionate |
Ointment and suspension presentations |
| VTAMA |
Tapinarof |
Nonsteroidal topical therapy |
| Zoryve |
Roflumilast |
Nonsteroidal PDE-4 inhibitor |
| Generic halobetasol |
Halobetasol propionate |
Low-cost steroid substitute |
| Generic tazarotene |
Tazarotene |
Low-cost retinoid substitute |
| Biologics |
IL-17, IL-23, and TNF inhibitors |
Higher efficacy for moderate-to-severe disease |
Duobrii’s target population is narrower than the total psoriasis market. Patients with extensive, severe, or treatment-resistant disease may move to biologics or other systemic therapies. The product is more directly exposed to patients with localized or moderate plaque psoriasis who need a stronger topical option.
What is the commercial differentiation of Duobrii?
Duobrii’s primary commercial advantage is convenience. A single lotion combines a corticosteroid and tazarotene, avoiding separate-product sequencing. The lotion vehicle may also improve cosmetic acceptability compared with ointments, which can increase adherence.
The main commercial limitations are:
- Halobetasol is a high-potency steroid with duration and anatomical-use restrictions.
- Tazarotene can cause irritation, erythema, peeling, and burning.
- Tazarotene is contraindicated during pregnancy because of fetal risk concerns.
- Payers may require generic steroids, calcipotriene combinations, or other topical products before coverage.
- The product is not positioned as a maintenance therapy for unrestricted long-term use.
The value proposition is strongest when physicians want rapid steroid activity with a retinoid component and want to avoid prescribing two separate topical products.
What is the FDA regulatory status of halobetasol propionate and tazarotene?
Duobrii remains an FDA-approved prescription product for adult plaque psoriasis. The approval was based on randomized clinical studies showing greater efficacy than vehicle in reducing psoriasis severity. The FDA label emphasizes corticosteroid risks, including hypothalamic-pituitary-adrenal axis suppression, skin atrophy, and systemic absorption. It also includes warnings related to pregnancy, ultraviolet exposure, and irritation associated with tazarotene. [1]
The product has no biologic license and does not receive the 12-year reference-product exclusivity available to biologics. Its regulatory protection is therefore driven primarily by patents, FDA-granted exclusivity tied to the original application, formulation know-how, and commercial execution.
When does halobetasol propionate and tazarotene lose exclusivity?
The original FDA approval date was May 2019. New chemical entity exclusivity for a combination product is not necessarily available in the same manner as for a novel single active ingredient because both active ingredients had established regulatory histories. Any applicable FDA exclusivity period must be distinguished from patent protection and must be verified in the current Drugs@FDA and Orange Book records. [2,3]
The key commercial issue is patent expiry, not biologic exclusivity. Duobrii’s protection is likely to depend on patents covering the fixed-dose combination, topical formulation, and methods of treating plaque psoriasis. The most relevant risk window begins when an applicant can file an ANDA or 505(b)(2) application with a Paragraph IV certification and withstand or resolve patent litigation.
The Orange Book should be treated as the controlling source for listed patents, pediatric exclusivity, and the latest patent expiration dates. Product-level public filings do not provide a reliable substitute for the current FDA listing.
What patents protect Duobrii?
The patent estate is expected to center on three technical categories:
Fixed-dose combination patents
These claims may cover the combination of halobetasol propionate and tazarotene at specified concentration ranges, including the commercial 0.01% and 0.045% strengths.
Lotion and vehicle patents
Formulation claims may cover the oil-in-water or emulsion vehicle, excipients, rheology, drug uniformity, stability, absorption, and skin tolerability. These patents can be more important than active-ingredient patents because halobetasol and tazarotene were previously known pharmaceutical ingredients.
Method-of-use patents
Method claims may cover once-daily treatment of plaque psoriasis using the combination, defined treatment periods, or sequential control of inflammatory and hyperproliferative symptoms.
The estate is stronger if it contains claims that cannot be readily designed around by changing the vehicle, concentration, dosing frequency, or excipient system. It is weaker if an applicant can demonstrate pharmaceutical equivalence using a different but acceptable topical formulation.
How strong is the patent estate for halobetasol propionate and tazarotene?
The estate has moderate commercial strength rather than biologic-level exclusivity strength.
Factors supporting protection include:
- Two active ingredients in a fixed-dose topical combination.
- A branded lotion vehicle that may be difficult to replicate precisely.
- Potential formulation and manufacturing know-how.
- A defined clinical use in plaque psoriasis.
- The possibility that a generic applicant must address multiple formulation and method claims.
Factors limiting protection include:
- Both active ingredients have long histories of pharmaceutical use.
- Generic halobetasol and generic tazarotene are available separately.
- Topical products can sometimes be challenged through alternative formulations.
- Payers have strong incentives to substitute lower-cost therapies.
- A 505(b)(2) applicant may seek approval based partly on existing literature and reference-product data.
The practical patent question is whether the listed claims require the exact commercial lotion or whether a competitor can design around the formulation while preserving the same active ingredients and therapeutic use.
Are Paragraph IV challenges likely?
Paragraph IV risk is credible once the product reaches a commercially attractive revenue level and the listed patents approach the final years of enforceability. A generic applicant could challenge patents covering the fixed-dose combination, formulation, or method of use.
Potential applicant strategies include:
- Filing an ANDA with a paragraph IV certification.
- Seeking approval for a different topical vehicle.
- Pursuing a 505(b)(2) application with a modified formulation.
- Carving out patented indications or dosing instructions.
- Demonstrating equivalence through in vitro release, permeation, or comparative clinical studies.
The likely litigation venue would be the U.S. District Court for the District of Delaware or another district selected by the innovator or challenger. A lawsuit filed within 45 days of notice of a Paragraph IV certification can trigger a statutory 30-month stay of ANDA approval, subject to court decisions and regulatory exceptions. [4]
No major publicly established settlement outcome should be assumed without a current review of FDA litigation records, court dockets, and company disclosures.
What generic entry risks exist?
Generic entry could occur through several pathways:
| Entry route |
Likely impact |
| Generic halobetasol alone |
Moderate substitution risk, but does not replicate the combination |
| Generic tazarotene alone |
Moderate substitution risk, especially for retinoid-oriented prescribing |
| Generic fixed-dose combination |
High direct substitution risk |
| 505(b)(2) lotion |
High risk if approved with comparable clinical positioning |
| Compounded combination |
Limited regulatory substitution, but possible local competition |
| Nonsteroidal topical competitor |
Moderate demand erosion without direct substitution |
A direct generic Duobrii equivalent would create the largest price threat. Separate generic products already create an indirect threat because payers can require physicians to prescribe the components individually.
What is the financial trajectory of Duobrii?
Bausch Health does not publicly disclose Duobrii revenue as a separate line item. The company reports at the segment or product-family level, which prevents a precise historical revenue series. This limits external valuation of the product’s contribution to Ortho Dermatologics and to consolidated Bausch Health revenue. [5]
The likely trajectory has four stages:
2019 to 2020: launch and access formation
The launch period focused on formulary placement, physician education, sampling, and patient support. The COVID-19 pandemic likely reduced dermatology visits and affected new prescription starts across topical therapies.
2021 to 2022: prescription expansion
Dermatology visits normalized, and the product gained exposure among physicians seeking a single-product alternative to separate steroid and retinoid therapy. Commercial performance remained dependent on prior authorization policies and copay support.
2023 to 2025: mature branded growth
The product’s growth opportunity shifted from initial awareness to repeat prescribing, payer expansion, and use in patients who had inadequate control or poor adherence with separate products. Revenue growth at this stage is more likely to be volume-driven than price-driven because payer pressure limits net pricing.
Pre-generic period: margin preservation
Before generic entry, the commercial focus is likely to move toward maximizing net revenue, defending formulary access, extending patient support, and preserving physician loyalty. The product can generate attractive gross margins as a branded topical, but discounts and specialty-pharmacy economics reduce net sales.
How does Duobrii compare with competing psoriasis drugs?
Duobrii has a distinct position between generic topical steroids and newer nonsteroidal or biologic therapies.
| Criterion |
Duobrii |
Generic steroid |
VTAMA or Zoryve |
Biologic |
| Convenience |
High, one product |
High |
High |
Moderate to low administration burden varies |
| Steroid exposure |
Yes |
Usually yes |
No |
No |
| Retinoid component |
Yes |
No |
No |
No |
| Long-term maintenance suitability |
Limited |
Limited by potency |
Generally stronger |
Strong |
| Cost to payer |
High versus generics |
Low |
High |
Very high |
| Appropriate severity |
Mild to moderate plaque psoriasis |
Mild to moderate |
Mild to moderate |
Moderate to severe |
| Direct generic threat |
Possible |
Existing |
Future risk |
Biosimilar risk varies |
Duobrii is more differentiated than a single-agent steroid but less durable as a long-term platform than nonsteroidal products. Its best commercial position is as a branded induction treatment or as an alternative for patients who need stronger topical efficacy without immediate escalation to systemic therapy.
What licensing and ownership issues affect the product?
Duobrii is commercialized by Ortho Dermatologics, part of Bausch Health. Public reporting does not provide a separately audited Duobrii royalty stream or product-level licensing economics. Any evaluation of licensing value should therefore focus on:
- Remaining patent term.
- Net sales after rebates and patient assistance.
- Payer coverage.
- Manufacturing cost and supply continuity.
- Direct generic or 505(b)(2) competition.
- Ability to expand into additional dermatology indications.
The product’s value is likely higher within a dermatology portfolio than as a standalone asset because sales infrastructure, field personnel, payer relationships, and physician targeting can be shared with other prescription skin products.
What is the outlook for biosimilar and generic competition?
Biosimilar risk is not applicable to Duobrii because it is a small-molecule topical drug, not a biologic. The relevant competitive threats are ANDA generics, 505(b)(2) products, compounded preparations, and branded nonsteroidal topicals.
The most disruptive entrant would be a therapeutically substitutable fixed-dose generic lotion. A generic version of only one active ingredient would exert pressure indirectly but would not fully reproduce the product’s convenience or combination profile.
Key Takeaways
- Duobrii is a once-daily fixed-dose lotion containing halobetasol propionate 0.01% and tazarotene 0.045%.
- The FDA approved it in May 2019 for adult plaque psoriasis.
- Its commercial differentiation is convenience, potency, and combined corticosteroid-retinoid activity.
- Product-level revenue is not publicly disclosed, preventing a precise financial trajectory.
- The product faces strong payer pressure from generic halobetasol, generic tazarotene, and lower-cost psoriasis treatments.
- Patent value is concentrated in fixed-dose combination, formulation, and method-of-use claims.
- Generic and 505(b)(2) entry are the principal exclusivity risks; biosimilar risk does not apply.
- The product’s financial value depends on the duration of enforceable formulation protection and the ability to maintain branded reimbursement.
- Duobrii is commercially stronger than a single-agent topical but less structurally protected than a biologic psoriasis franchise.
FAQs
Is Duobrii the same as halobetasol cream?
No. Duobrii is a lotion containing halobetasol propionate and tazarotene. Halobetasol cream or ointment contains halobetasol alone and does not provide the retinoid component.
Can Duobrii be used continuously for psoriasis maintenance?
The FDA label limits treatment to once daily for up to eight weeks. Long-term continuous use is restricted by the safety profile of halobetasol and should not be inferred from the product’s efficacy data.
Does Duobrii have a biosimilar?
No. Duobrii is a small-molecule topical combination and is not eligible for biosimilar competition under the biologics pathway.
Could a generic combine halobetasol and tazarotene in a different lotion?
Potentially. A challenger could pursue an ANDA or 505(b)(2) pathway depending on formulation similarity, bioequivalence requirements, labeling, and the scope of enforceable patents.
What is the main investment risk for Duobrii?
The main risk is erosion of branded pricing before the product reaches full commercial maturity. Generic substitution, payer step therapy, competing nonsteroidal topicals, and limited product-level disclosure make future revenue difficult to forecast with precision.
References
- U.S. Food and Drug Administration. (2019). Duobrii (halobetasol propionate and tazarotene) lotion prescribing information.
- U.S. Food and Drug Administration. (n.d.). Drugs@FDA: FDA-approved drugs.
- U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book.
- U.S. Food and Drug Administration. (2024). ANDA submissions: Amendments and approvals.
- Bausch Health Companies Inc. (2024). Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.
